topiramate/phentermine / Generic mfg. - LARVOL DELTA

Are glucagon-like peptide-1 analogs better answer for obese patients with metabolic dysfunction associated steatotic liver disease than bariatric surgery? Real-world evidence (EASL 2025) - "Primary outcomes were the development of decompensated cirrhosis and all-cause mortality in patients treated with GLP-1 analogs (semaglutide, tirzepatide, dulaglutide, exenatide, lixisenatide) compared to patients treated with bariatric surgery (gastric bypass, sleeve gastrectomy, biliopancreatic diversion with duodenal switch, vertical band gastroplasty)... Out of 545,931 patients with MASLD, 73,339 (13.44%, median 733 days) patients were treated with GLP1 analog, 38,541 (7.06%, median 690 days) sodium-glucose cotransporter 2 (SGLT 2) inhibitors and 29,917 (5.48%, median 832 days) received other weight loss medications (naltrexone, topiramate or phentermine)... GLP-1 analogs are increasingly being used in patients with MASLD. GLP-1 analogs and bariatric surgery reduce the risk of decompensated cirrhosis in obese patients with MASLD. Our results indicate that patients with MASLD treated with GLP-1 analogs have a lower risk of decompensated cirrhosis and better overall..."

Bariatric surgery • Clinical • HEOR • Real-world • Real-world evidence • Surgery • Fibrosis • Gastrointestinal Disorder • Genetic Disorders • Hepatocellular Cancer • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Obstructive Sleep Apnea • Oncology • Respiratory Diseases • Sleep Apnea • Sleep Disorder • Solid Tumor

Efficacy and Safety of Phentermine Plus Topiramate in Patients with Overweight or Obesity (ECO 2025) - No abstract available

Clinical • Late-breaking abstract • Genetic Disorders • Obesity

Efficacy of Phentermine/Topiramate Extended Release in Weight Management and Metabolic Profiles (ECO 2025) - No abstract available

Clinical

Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) (clinicaltrials.gov) - P4 | N=150 | Recruiting | Sponsor: The Cleveland Clinic | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

Antidepressant and antiobesity drug-induced serotonin syndrome complicated by multiple organ injury: A case report. (PubMed, Medicine (Baltimore)) - "This case highlights that SS should be considered as an etiology of unexplained episodes of altered mental status and neuromuscular abnormalities. Rarely, this condition can be complicated by multiple organ injury, involving conditions such as rhabdomyolysis, renal failure, SCM and PTE. Thus, physicians must be aware of the various and atypical manifestations of serotonin syndrome in order to avoid missing the diagnosis of a potentially fatal condition."

Journal • Cardiomyopathy • Cardiovascular • CNS Disorders • Critical care • Depression • Genetic Disorders • Nephrology • Obesity • Psychiatry • Pulmonary Embolism • Renal Disease

Preoperative weight loss by noninvasive approach in patients with obesity scheduled for bariatric and metabolic surgery: an update narrative review of indications and results available until 2024. (PubMed, Updates Surg) - "In this context, concerning dietary approaches, several dietary protocols have been introduced over time, among which very low-calorie diets and very low energy ketogenic therapy are widely prescribed; however, larger randomized-controlled trials (RCTs) with well-defined dietary protocols are necessary to make definitive conclusions. Obesity management medications, such as the lipase inhibitor orlistat, phentermine/topiramate, naltrexone/bupropion, the glucagon-like peptide-1 receptor agonists (GLP-1RAs) liraglutide and semaglutide, and the novel dual glucose dependent insulinotropic peptide (GIP)/GLP-1 receptor agonist tirzepatide, has shown to be effective in promoting PreopWL before MBS; however, larger, well-designed RCTs are needed to establish optimal treatment protocols and assess their true benefits in patients scheduled for MBS. Space-occupying devices such as the swallowable intragastric balloon and hydrogel capsules, represent a promising tools but..."

Journal • Review • Genetic Disorders • Hepatology • Obesity

The POuND OUT study: phentermine and topiramate for uric acid stone prevention (AUA 2025) - "In this feasibility study, combination phentermine/topiramate was well tolerated and had similar effect as standard therapy on 18 month kidney CT volume while reducing total body weight >10%. Individuals on study drugs also had fewer stone procedures, lower HbA1c levels, and higher urine pH than controls. This data provides a framework to study the impact of this novel alternative UAN therapy in a wider range of obese and diabetic populations."

Diabetes • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Renal Calculi

Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review. (PubMed, Cureus) - "This literature review evaluates and compares the effectiveness of four pharmacological agents semaglutide, liraglutide, orlistat, phentermine, and emerging agents like setmelanotide, amycretin, retatrutide, cagrilintide, and cotadutide in managing weight loss among obese. A detailed analysis was conducted on their mechanisms of action, dosing regimens, efficacy in weight loss, safety profiles, and their impact on obesity-related comorbidities. Although all agents presented distinct benefits, side effects such as gastrointestinal discomfort with orlistat and GLP-1 receptor agonists, and potential dependency with phentermine, necessitate tailored treatment approaches. This review highlights the importance of integrating pharmacotherapy with lifestyle interventions to achieve sustainable weight management and identifies areas for future research to optimize therapeutic outcomes for individuals with obesity."

HEOR • Journal • Review • Cardiovascular • Gastrointestinal Disorder • Genetic Disorders • Obesity

Weight Gain Prevention in Adolescents and Young Adults (clinicaltrials.gov) - P3 | N=140 | Not yet recruiting | Sponsor: University of Minnesota

New P3 trial • Genetic Disorders • Obesity

Older Adults' Views on Insurance Coverage for Weight Management Medications. (PubMed, JAMA Netw Open) - "Medicare and many commercial insurers do not cover US Food and Drug Administration-approved weight management medications, such as incretin mimetics (semaglutide, tirzepatide, and liraglutide), bupropion-naltrexone, and phentermine-topiramate). In this survey study of older US adults, most participants agreed that Medicare should cover weight management medications and more than half of those with BMI of 30 or greater were interested in using them. These results should inform decisions to include weight management medications in the Medicare and commercial insurance programs, as well as utilization policies to control health care costs."

Journal • Reimbursement • US reimbursement

Mechanisms and treatment of obesity-related hypertension-Part 2: Treatments. (PubMed, Clin Kidney J) - "In this context, first-generation anti-obesity drugs such as orlistat, phentermine/topiramate, and naltrexone/bupropion are poorly effective, whereas second-generation incretin receptor agonists, including the GLP-1 receptor agonists liraglutide and semaglutide, and in particular the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) co-agonist tirzepatide, substantially contribute to effective WL and BP control in obesity. Integrating a multifaceted weight-based approach with other strategies, such as antihypertensive drugs and renal denervation, could specifically target the main neuro-hormonal and renal pathophysiological mechanisms of obesity-related hypertension, including sympathetic-nervous and renin-angiotensin-aldosterone systems overactivity, salt retention, and volume expansion. This comprehensive strategy can provide a personalized algorithm for managing hypertension in obesity within the context of "precision medicine" principles."

Journal • Review • Cardiovascular • Genetic Disorders • Hypertension • Obesity

The Institute for Clinical and Economic Review's Incorrect Use of Incremental Cost-Effectiveness Ratios (ISPOR 2025) - "ICERO evaluated semaglutide, liraglutide, phentermine/topiramate, and bupropion/naltrexone (each added to lifestyle modification) and lifestyle alone. Despite its non-standard approach in calculating ICERs versus a common alternative, ICERO correctly suggested phentermine/topiramate was cost-effective in its base case analysis. However, utilizing its approach will generally lead to incorrect conclusions as we have shown here in analyses beyond the base case. Incorrect conclusions, if implemented, can negatively affect healthcare system the efficiency."

Clinical • Cost effectiveness • HEOR • Review • Genetic Disorders • Obesity

The Evolving Role of Weight Loss Pharmacotherapy. (PubMed, Gastroenterol Hepatol (N Y)) - "Traditional pharmacotherapy includes phentermine/topiramate and bupropion/naltrexone, both of which have been shown to aid in weight loss. Despite their effectiveness, barriers to widespread use include their cost, insurance approval, and side effect profile. Further studies are underway examining the role of pharmacotherapy in conjunction with endoscopic bariatric therapies as well as bariatric surgery."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Efficacy of phentermine/topiramate extended release in weight management and metabolic profiles: A multicentre study in South Korea. (PubMed, Diabetes Obes Metab) - "The study suggests phentermine/topiramate ER is an effective option for obesity management in a South Korean population, though long-term adherence remains a challenge."

Journal • CNS Disorders • Dyslipidemia • Genetic Disorders • Insomnia • Obesity • Sleep Disorder • Xerostomia

Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. (PubMed, JAMA Health Forum) - "Lifestyle modification with naltrexone-bupropion, phentermine-topiramate, semaglutide, or tirzepatide vs lifestyle modification alone. This economic evaluation found that although tirzepatide and semaglutide offered substantial long-term health benefits, they were not cost-effective at current net prices. Efforts to reduce the net prices of new antiobesity medications are essential to ensure equitable access to highly effective antiobesity medications."

HEOR • Journal • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

VIVUS Launches QSYMIA in the United Arab Emirates (GlobeNewswire) - "VIVUS LLC...announced the market approval of QSYMIA (phentermine and topiramate extended-release capsules) CIV in the United Arab Emirates (UAE) for treatment of overweight and obesity in adults and pediatric patients, age 12 and older....The World Obesity Federation estimates that by 2035, approximately 7.5 million adults, children, and adolescents in the UAE will be overweight or living with obesity."

Launch non-US • Obesity

Sequential or CombinaTion Anti-obesitY Medication with Muscle Preservation for Weight Loss and MaintEnance: a PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) (clinicaltrials.gov) - P4 | N=150 | Not yet recruiting | Sponsor: The Cleveland Clinic

New P4 trial • Genetic Disorders • Obesity

Pharmacological interventions for addressing pediatric and adolescent obesity: A systematic review and network meta-analysis. (PubMed, PLoS One) - "The study found that semaglutide outperformed other AOMs in reducing BMI and additional weight-related outcomes in children and adolescents with obesity, while PHEN/TPM showed comparable efficacy."

Clinical • Journal • Retrospective data • Review • Genetic Disorders • Obesity • Pediatrics

Risk of Glaucoma in Non-Diabetic Patients using a Glucagon Like Peptide-1 Receptor Agonist. (PubMed, Ophthalmology) - "In non-diabetic patients, the use of GLP-1RAs exhibited a significantly reduced risk of POAG and ocular hypertension compared to alternative weight loss therapy at 3- and 5-year intervals. These results underscore the utility of GLP-1RAs in glaucoma prevention and management and highlights yet another potential indication for this class of medications beyond glycemic control."

Journal • Cardiovascular • Genetic Disorders • Glaucoma • Metabolic Disorders • Obesity • Ophthalmology

Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: University of Minnesota | N=143 ➔ 100

Enrollment change • Genetic Disorders • Obesity • CRP

Efficacy and Safety of Phentermine/Topiramate in Youth with Hypothalamic Obesity (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Seattle Children's Hospital | Initiation date: Aug 2024 ➔ Mar 2025

Trial initiation date • Brain Cancer • CNS Tumor • Genetic Disorders • Hypothalamic Injury-associated Obesity • Obesity • Oncology

Cutting-Edge Approaches to Obesity Management: The Latest Pharmacological Options. (PubMed, Endocrinol Metab Clin North Am) - "The seven FDA-approved anti-obesity medications are phentermine, orlistat, phentermine/topiramate ER, naltrexone SR/bupropion SR, liraglutide 3.0 mg, semaglutide 2.4 mg, and tirzepatide. Obesity is a chronic disease and these medications should be prescribed with the intention of long-term use. In this article, we summarize data from phase 3 clinical trials which led to drug approval, and we review the clinical indications, mechanism of action, dosing/administration, side effects, drug interactions and contraindications for each medication."

Journal • Review • Genetic Disorders • Obesity

Association of long-term weight management pharmacotherapy with multiple health outcomes: an umbrella review and evidence map. (PubMed, Int J Obes (Lond)) - "This umbrella review identified significant beneficial associations between pharmacotherapies and anthropometric measures, lipid profile, blood pressure, glycemic profile, and quality-of-life outcomes in individuals with overweight or obesity. In addition, the umbrella review highlighted safety considerations. The findings affirm the efficacy of the six pharmacotherapies in promoting weight loss in this demographic. Further clinical trials with long-term follow-up are essential to evaluate the effects of these pharmacotherapies on clinical outcomes, including cancer, cardiovascular events, and mortality."

Clinical • HEOR • Journal • Review • Cardiovascular • Genetic Disorders • Obesity • Oncology

Efficacy of Oral Medication in Weight Loss Management: A Systematic Review and Network Meta-Analysis. (PubMed, Clin Ther) - "Oral antiobesity drugs provide better weight loss than placebo. However, some side effects can be incurred by utilizing the drug for weight loss, especially related to the gastrointestinal system. Nonetheless, in clinical settings, consideration should be given to particular patients to reduce risk of side effects."

Journal • Retrospective data • Review • Gastrointestinal Disorder • Genetic Disorders • Obesity

Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis. (PubMed, EClinicalMedicine) - "Considering cardiometabolic risk factors, tirzepatide shows the best blood pressure- and glucose-lowering benefits, while semaglutide and liraglutide reduce the risk of MACEs...Phentermine/topiramate should be used with caution due to its higher risk of psychological side effects. Despite limitations related to study heterogeneity, these findings provide valuable insights for weight management strategies across diverse individuals. National Natural Science Foundation of China, Leading Talents Program of Hunan Province, and Fundamental Research Funds for the Central Universities of Central South University."

Journal • Retrospective data • Cardiovascular • CNS Disorders • Depression • Gastrointestinal Disorder • Genetic Disorders • Mood Disorders • Obesity • Psychiatry • Sleep Disorder